Advertisement

Antiepileptic Drugs

  • H. J. Zimmerman
  • K. G. Ishak
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 121)

Abstract

The frequent, concurrent use of several drugs has hampered the evaluation of the hepatotoxic potential of individual anticonvulsants. Nevertheless, it has been possible to characterize the hepatic injury associated with the commonly used anticonvulsive agents. Although at least 30 drugs have seen use as anticonvulsants, only 3 have drawn attention as important causes of hepatic injury (ZIMMERMAN and MADDREY 1993). These include phenytoin, carbamazepine, and valproic acid. While this chapter will focus on these three agents, reference will be made to other anticonvulsants that have been implicated in hepatic injury (Table 1). The hepatic injury produced by anticonvulsants is quite uniform. That associated with phenytoin and valproic acid is predominately hepatocellular. Rare instances of phenytoin-induced injury have been cholestatic, and carbamazepine jaundice may be either hepatocellular or cholestatic.

Keywords

Valproic Acid Antiepileptic Drug Hepatic Injury Sodium Valproate Carnitine Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aiges HW, Daum F, Olson M et al. (1980) The effects of phenobarbital and diphenylhydantoin on liver function and morphology. J Pediatr 97:22PubMedGoogle Scholar
  2. Andreasen PB, Lyngbye J , Trolle E (1973) Abnormalities in liver function tests during long-term diphenylhydant oin therapy in epileptic out-patients. Acta Med Scand 194:261PubMedGoogle Scholar
  3. Anthony J (1970) Malignant lymphoma associated with hydantoin drugs. Arch Neurol 22:450PubMedGoogle Scholar
  4. Bayer AS, Targan SR, Pitchon HE, Guze LB (1976) Dilantin toxicity: miliary pulmonary infiltrates and hypoxemia. Ann Intern Med 85:475PubMedGoogle Scholar
  5. Bertram PD, Taylor RJ (1980) Carbamazepine hepatotoxicity: clinical and histopathological features. Am J Gastroenterol 74:78Google Scholar
  6. Bjorge SM, Baillie TA (1985) Inhibition of medium-chain fatty acid β-oxidation in vitro by valproic acid and its unsaturated metabolic, 2-n-propyl-4-pentenoic acid. Biochem Biophy Res Comm 132:245Google Scholar
  7. Bonazzi P, Novelli G, Macarri G et al. (1986) Effect of drug pretreatment on the interaction of valproic acid with the liver cell: functional and ultrastructural data. Ital J Gastroenterol 18:79Google Scholar
  8. Bowdle TA, Patel IH, Wilensky AJ et al. (1979) Hepatic failure from valproic acid (letter). N Engl J Med 301:435PubMedGoogle Scholar
  9. Braverman IM, Levin J (1963) Dilantin-induced serum sickness: case report and inquiry into its mechanisms. Am J Med 35:418PubMedGoogle Scholar
  10. Brown M, Schubert T (1986) Phenytoin hypersensitivity hepatitis and mononucleosis syndrome. J Clin Gastroenterol 4:469Google Scholar
  11. Browne TR (1980) Valproic acid. Med lntell 302:661Google Scholar
  12. Brukher AB, Joustra UH (1966) Leberbeschadiging door carbamazepine. Ned Tijdochr Genesked 110:1181Google Scholar
  13. Buchanan RRC, Gordon DA, Muckle TJ et a1 (1980) The eosinophilic fascitis syndrome after phenytoin (dilantin) therapy. J Rheumatol 7:733PubMedGoogle Scholar
  14. Buchi KN, Gray PD, Rollins DE (1984) Protection against sodium valproate injury in isolated hepatocytes by a-tocopherol and N,N’ -diphenyl-p-phenylenediamine. J Clin Pharmacol 24:148PubMedGoogle Scholar
  15. Bunch SE, Castleman WL, Paldwin BH, et a1. (1985) Effects of long-term primidone and phenytoin administLltion on canine hepatic function and morphology. Am J Vet Res 46:105PubMedGoogle Scholar
  16. Butscher WC, Gallager HS (1952) Fatal hepatic necrosis occurring during therapy with phethenylate sodium. JAMA 148:535Google Scholar
  17. Campbell CB, McGuffie C, Weedon AP, Powell LW (1977) Cholestatic liver disease associated with diphenylhydantoin therapy. Am J Dig Dis 22:255PubMedGoogle Scholar
  18. Carter S, Scearra D, Merritt HH (1950) Phenylacetylurea in the treatment of convulsive seizures. Dis Nerv Sys 11:139Google Scholar
  19. Chaiken BH, Goldberg BI, Segal JP (1950) Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 242:897PubMedGoogle Scholar
  20. Coude FX, Grimber G, Pelet A et a1. (1983a) Action of the antiepileptic drug valproic acid on fatty acid oxidation in isolated rat hepatocytes. Biochem Biochys Res Commun 115:730Google Scholar
  21. Coude FX, Grimber G, Parvy P et a1. (1983b) Inhibition of ureagenesis by valproate in rat hepatocytes. Biochem J 216:233PubMedGoogle Scholar
  22. Coulter DL (1984) Carnitine deficiency: a possible mechanism for valproate hepatotoxicity. Lancet 1:689PubMedGoogle Scholar
  23. Coulter DL, Wu H, Allen RJ (1980) Valproic acid therapy in childhood epilepsy. JAMA 244:785PubMedGoogle Scholar
  24. Deutsch J, Fritsch G, Golles J, Semmelrock HJ (1986) Effects of anticonvulsive drugs on the activity of gammaglutamytransferase and aminotransferases in serum. J Pediatr Gastroenterol Nutr 542Google Scholar
  25. Dhar GJ, Pierach CA, Ahamed PN, Howard RB (1974) Diphenylhydantoin-induced hepatic necrosis. Postgrad Med 56:128PubMedGoogle Scholar
  26. Dreifuss FE, Santilli N (1986) Valproic acid hepatic fatalities: analysis of United States cases. Neurology 36 [Suppl 1]:175Google Scholar
  27. Dreifuss FE, Langer DH, Moline KA, Maxwell JE (1989) Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 39:201PubMedGoogle Scholar
  28. Easton JD (1972) Potential hazards of hydantoin use. Ann Intern Med 77:998PubMedGoogle Scholar
  29. Elitsur Y (1990) Pemoline (Cylert)-induced hepatotoxicity (letter). J Pediatr Gastroenterol Nutr 11 :143PubMedGoogle Scholar
  30. Engel JN, Mellul VG, Goodman DBP (1986) Phenytoin hypersensitivity: a case of severe acute rhabdomyolysis. Am J Med 81:928PubMedGoogle Scholar
  31. Fellows WR (1969) A case of aplastic anemia and pancytopenia with Tegretol therapy. Headache 9:92PubMedGoogle Scholar
  32. Forbes GM, Jeffrey GP, Shilkin KB, Reed WD (1992) Carbamazepine hepatotoxicity: another case of the vanishing bile duct syndrome. Gastroenterology 102:1385PubMedGoogle Scholar
  33. Frame B (1971) Hypocalcemia and osteomalacia associated with anticonvulsant therapy. Ann Intern Med 74:294PubMedGoogle Scholar
  34. Gerber N, Dickinson RG, Harland RD et a1. (1979) Reye-like syndrome associated with valproic acid therapy. J Pediatr 95:142PubMedGoogle Scholar
  35. Gibbs FA, Everett GM, Richards RK (1949) Phenurone in epilepsy. Dis Nerv Sys 10:47Google Scholar
  36. Glasgow AM, Chase HP (1975) Production of the features of Reye’s syndrome in rats with 4-pentenoic acid. Pediatr Res 9:133PubMedGoogle Scholar
  37. Gram L, Bentsen KD (1983) Hepatic toxicity of antiepileptic drugs: a review. Acta Neural Scand [Suppl] 97:81Google Scholar
  38. Granneman CR, Wang S-I, Kesterson JW et a1. (1984) The hepatotoxicity of valproic acid and its metabolites in rats. II. Intermediary and valproic acid metabolism. Hepatology 4:1153PubMedGoogle Scholar
  39. Green SH (1984) Sodium valproate and routine liver function tests. Arch Dis Child 59:813PubMedGoogle Scholar
  40. Gropper AL (1956) Diphenylhydantoin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 242:897Google Scholar
  41. Hadzie N, Portmann B, Davies ET et al. (1990) Mieli-Vergani G: acute liver failure induced by carbamazepine. Arch Dis Child 65:315Google Scholar
  42. Hjelm M, DeSilva LVK, Seakins IWT (1986) Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. Br Med J 292:23Google Scholar
  43. Hopen G, Nesthus I, Laerum OD (1981) Fatal carbamazepine-associated hepatitis: report of two cases. Acta Med Scand 210:333PubMedGoogle Scholar
  44. Hutterer F, Schaffner F, Klion FM, Popper H (1968) Hypertrophic hypoactive smooth endoplasmic reticulum: a sensitive indicator of hepatotoxicity exemplified by dieldrin. Science 161:1017PubMedGoogle Scholar
  45. Jacobsen NO, Mosekilde L, Myhre-Jensen O et al. (1976) Liver biopsies in epileptics during anticonvulsant therapy. Acta Med Scand 199:345PubMedGoogle Scholar
  46. Jaffe SL (1989) Pemoline and liver function (letter). J Am Acad Adolesc Psychiatry 28:457Google Scholar
  47. Jeavons PM (1982) Valproate toxicity. In: Woodbury DM, Penry JK, Pippenger CE (eds) Antiepileptic drugs. Raven, New York, pp 601–610Google Scholar
  48. Jeavons PM (1983) Hepatotoxicity of antiepileptic drugs. In: Oxley J, Janz D, Meinardi H (eds) Chronic toxicity of antiepileptic drugs. Raven, New York. pp 1–45Google Scholar
  49. Jeavons PM (1984) Non-dose-related side effects of valproate. Epilepsia 25:550Google Scholar
  50. Jezequel AM. Orlandi F (1976) Unusual residual bodies in human liver cells. J Ultrastruct Res 57:87PubMedGoogle Scholar
  51. Jezequel AM. Bonazzi P, Novelli G et al. (1984) Early structural and functional changes in liver of rats treated with single dose of valproic acid. Hepatology 4: 1159PubMedGoogle Scholar
  52. Jimemez-Rodriguezvila M, Caro-Paton A, Duenas-Laita A et al. (1985) Histological. ultrastructural and mitochondrial oxidative phosphorylation studies in livers of rats chronically treated with oral valproic acid. J Hepatol 1 :453Google Scholar
  53. Jimenez-Rodriguezvila M, Caro-Paton A, Conde M et al. (1986) Side effects of sodium valproate, mainly related to its hepatic and pancreatic toxicity. Int J Clin Pharm Res 6:271Google Scholar
  54. Kazamatsuri H (1970) Elevated serum alkaline phosphatase levels in epilepsy during diphenyldantoin therapy. N Engl J Med 283:1411PubMedGoogle Scholar
  55. Keeffe EB, Sunderland MC, Gabourel JD (1986) Serum gamma-glutamyl transpeptidase activity in patients receiving chronic phenytoin therapy. Dig Dis Sci 31:1056PubMedGoogle Scholar
  56. Keene DL, Humphrey P, Carpenter B, Fletcher JP (1982) Valproic acid producing a Reye-like syndrome. Le J Can Sci Neurol 00:435Google Scholar
  57. Kesterson JW, Granneman GR, Machinist JM (1984) The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4: 1143PubMedGoogle Scholar
  58. Kingsley E, Gray P, Tolman KG et al. (1983) The toxicity of metabolites of sodium valproate in cultured hepatocytes. J Clin Pharmacol 23: 178PubMedGoogle Scholar
  59. Kleckner HB, Yakulis V, Heller P (1975) Severe Hypersensitivity to diphenylhydantoin with circulating antibodies to the drug. Ann Intern Med 83:522PubMedGoogle Scholar
  60. Lapes MJ, Vivacqua RJ, Antoniades K (1976) Immunoblastic lymphadenopathy associated with phenytoin (diphenylhydantoin). Lancet 1: 198PubMedGoogle Scholar
  61. Larrey D, Hadengue A, Pessayre D (1987) Carbamazepine-induced acute cholangitis. Dig Dis Sci 32:354Google Scholar
  62. Laub MC. Paetzke-Brunner I, Jaeger G (1986) Serum carnitine during valproic acid therapy. Epilepsia 27:559PubMedGoogle Scholar
  63. Leard G, Greer WER, Kaufman IC (1949) Hepatitis, exfoliative dermatitis and abnormal bone marrow occurring during tridione therapy: report of case with recovery. N Engl J Med 240:962PubMedGoogle Scholar
  64. Leblanc JL, Feldman A (1961) Trimethadione hepatitis: a case report and review of trimethadione toxicity. Can Med Assos J 85:200Google Scholar
  65. Levander HG (1980) Granulomatous hepatitis in a patient receiving carbamazepine. Acta Med Scand 208:333PubMedGoogle Scholar
  66. Levy M, Goodman MW, VanDyne BJ, Sumner HW (1981) Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 95:64PubMedGoogle Scholar
  67. Levy RW, Simmons DJ, Aronson S (1950) Fatal hepatorenal syndrome associated with phenurone therapy. N Engl J Med 242:933PubMedGoogle Scholar
  68. Lewis JH, Zimmerman HJ, Garrett CT, Rosenburg E (1982) Valproate-induced hepatic steatogenesis in rats. Hepatology 2:870PubMedGoogle Scholar
  69. Luke DR, Rocci ML, Schaible DH, Ferguson RK (1986) Acute hepatotoxicity after excessively high doses of carbamazepine on two occasions. Pharmacotherapy 6:108PubMedGoogle Scholar
  70. Mandelbaum H, Kane LJ (1941) Dilantin sodium poisoning: report of a case with dermatitis exfoliative, pyrexia and hepatic and splenic enlargement. Arch Neurol Psychiatr 45:769Google Scholar
  71. Martindale (1982) The extra pharmacopeia, 28th edn. Pharmaceutical Press, pp 437Google Scholar
  72. Melegh B, Kerner J, Acsadi G et al. (1990) L-Carnitine replacement therapy in chronic valproate treatment. Neuropediatrics 21:40PubMedGoogle Scholar
  73. Merritt HH, Putnam TJ (1938) Sodium diphenylhydantoin in the treatment of convulsive disorders. JAMA 111:1068Google Scholar
  74. Michael JR, Mitch WE (1976) Reversible renal failure and myositis caused by phenytoin hypersensitivity. JAMA 36:2773Google Scholar
  75. Michael JR, Rudin ML (1981) Acute pulmonary disease caused by phenytoin. Ann Intern Med 95:452PubMedGoogle Scholar
  76. Mitchell MC, Boitnott JK, Arregue A, Maddrey W (1981) Granulomatous hepatitis associated with carbamazepine therapy. Am J Med 71:733PubMedGoogle Scholar
  77. Moore JR, Williams THC, Talbot FC, Tanner MS (1984) Heterozygous antitrypsin deficiency and valproate hepatotoxicity. Lancet 1:221PubMedGoogle Scholar
  78. Mullick FG, Ishak KG (1980) Hepatic injury associated with diphenylhydantoin therapy: a clinicopathologic study of 20 cases. Am J Clin Pathol 74:442PubMedGoogle Scholar
  79. Murphy JV, Marguardt K (1982) Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 39:591PubMedGoogle Scholar
  80. Murphy JV, Marquardt KM, Shug AL (1985) Valproic acid associated abnormalities of carnitine metabolism. Lancet 1:820PubMedGoogle Scholar
  81. Murphy MJ, Lyon LW, Taylor JW, Mills G (1981) Valproic acid associated pancreatitis in an adult. Lancet 1:41PubMedGoogle Scholar
  82. Nordin G, Hemdal I, Olsson J-E, Rolny P (1982) Liver damage and anti-epileptic drugs. Acta Neurol Scand 65 [Suppl 90]:199Google Scholar
  83. Offermann G (1981) Chronic anti epileptic drug treatment and disorders of mineral metabolism. In: Oxley J, Janz D, Meinardi H (eds) Chronic toxicity of antiepileptic drugs. Raven, New York, pp 175–184Google Scholar
  84. Ohtani Y, Ebdo F, Matsuda I (1982) Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101:782PubMedGoogle Scholar
  85. Parker PH, Helineck GL, Guisan FK, Greene HL (1981) Recurrent pancreatitis induced by valproic acid. Gastroenterology 80:826PubMedGoogle Scholar
  86. Parker W A, Shearer CA (1979) Phenytoin hepatotoxicity: a case report and review. Neurology 29:175PubMedGoogle Scholar
  87. Powell PR, Jackson JM, Williams R (1984) Hepatotoxicity to sodium valproate. A review. Gut 25:673Google Scholar
  88. Pryles CV, Burnett JM, Livingston S (1952) Acute hepatic necrosis with death occurring during phethenylate sodium therapy. Report of two cases.JAMA 148:536Google Scholar
  89. Qureshi IA, Letarte J, Tuchweber B et al. (1985) Hepatotoxicity of sodium valproate in ornithine transcarbamylase-deficient mice. Toxicol Lett 25:297PubMedGoogle Scholar
  90. Rettie AE, Rettenmeier AW, Howalk WN, Baille TA (1986) Cytochrome P-450-catalyzed formation of 4-VP A, a toxic metabolite of valproic acid. Science 235:890Google Scholar
  91. Riera Velasco JR, Rodrigo Saez LR et al. (1986) Hepatitis cronica activa por difenilhidantoinas. Med Clin (Barc) 87:214Google Scholar
  92. Ritchie EB, Kolb W (1942) Reaction to sodium diphenylhydantoin ate (dilantin sodium): hemorrhagic erythema multiforme terminating fatally. Arch Dermatol Syph 46:856Google Scholar
  93. Rozas I, Camina MF, Paz JM et al. (1990) Effects of acute valproate administration on carnitine metabolism in mouse serum and tissues. Biochem Pharmacol 39:181PubMedGoogle Scholar
  94. Saltzstein SL, Ackerman LV (1959) Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 12:164PubMedGoogle Scholar
  95. Schnabel R, Lahl R (1964) Leberparenchymnekrosen durch das neue Antiepilepticum alpha-Acetoxyphenuron. Bericht uber tierexperimentelle Untersuchungen und 4 letal verlaufene Faile. Zentralbl Alig Pathal Anat 106:42Google Scholar
  96. Scheffner D (1988) Fatal liver failure in 16 children with valproate therapy. Epilepsia 29:530PubMedGoogle Scholar
  97. Shapiro P A, Antonioli DA, Peppercorn MA (1980) Barbiturate-induced submassive hepatic necrosis: report of a case and review of the literature. Am J Gastroenterol 74:270PubMedGoogle Scholar
  98. Shear NH, Spielberg SP, Cannon M, Miller M (1988) Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.J clin Invest 82:1826–1832PubMedGoogle Scholar
  99. Sherard ES, Steinman GS, Couri D et al. (1980) Treatment of childhood epilepsy with valproic acid. Neurology 30:31PubMedGoogle Scholar
  100. Siegel S, Berkowitz J (1961) Diphenylhydantoin (dilantin) hypersensitivity with infectious mononucleosis-like syndrome and jaundice. J Allergy 32:447Google Scholar
  101. Soffer EE, Taylor RJ, Bertram PD et al. (1983) Carbamazepine-induced liver injury. South Med J 76:681PubMedGoogle Scholar
  102. Spechler SJ, Sperber H, Doos WG et al. (1981) Cholestasis and toxic epidermal necrolysis associated with phenytoin sodium ingestion: the role of bile duct injury. Ann Intern Med 95:455PubMedGoogle Scholar
  103. Spielberg SP, Gordon GB, Blake DA et al. (1981) Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 305:722PubMedGoogle Scholar
  104. Spillane J (1964) The treatment of trigeminal neuralgia: preliminary experience with tegretol. Practitioner 192:71PubMedGoogle Scholar
  105. Stricker BHCH (1992) Drug-induced hepatic injury, 2nd edn. Elsevier. Amsterdam, pp 412–460Google Scholar
  106. Suchy FJ, Balistreri WF, Buchino JJ et al. (1979) Acute hepatic failure associated with the use of sodium valproate: report of two fatal cases. N Engl J Med 300:962PubMedGoogle Scholar
  107. Sugimoto T, Nishida N, Yasuhara A et al. (1983) Reye-like syndrome associated with valproic acid. Brain Dev 5:334PubMedGoogle Scholar
  108. Sugimoto T, Araki A, Nishida N, Kobayashi Y et al. (1987a) Hepatotoxicity in rat following administration of valproate: effect of L-carnitine administration. Epilepsia 28:373–377PubMedGoogle Scholar
  109. Sugimoto T, Woo M, Nishida N et al. (1987b) Hepatotoxicity in rat following administration of valproic acid. Epilepsia 28:142PubMedGoogle Scholar
  110. Sussman NM, McLain LW (1979) A direct hepatotoxic effect of valproic acid. JAMA 242:1173PubMedGoogle Scholar
  111. Takeuchi T, Sugimoto T, Nishida N, Kobayashi Y (1988) Protective effect of d,lcarnitine on valproate-induced hyperammonemia and hypoketonemia in primary cultured rat hepatocytes. Biochem Pharmacol 37:2255PubMedGoogle Scholar
  112. Tanaka K Kean EA, Johnson B (1976) Jamaican vomiting sickness: biochemical investigation of two cases. N Engl J Med 295:461PubMedGoogle Scholar
  113. Taylor JW, Stein MN, Murphy MJ, Mitros FA (1984) Cholestatic liver dysfunction after long-term phenytoin therapy. Arch Neurol 41:500PubMedGoogle Scholar
  114. Ting S, Dunsky EH (1982) Diphenylhydantoin-induced hepatitis. Ann Allergy 48:331PubMedGoogle Scholar
  115. Tomsick RS (1983) The phenytoin syndrome. Cutis 32:535PubMedGoogle Scholar
  116. Tripp JH, Hargreaves T, Anthony PP et al. (1981) Sodium valproate and ornithine carbamyl transferase deficiencies. Lancet 1:1165PubMedGoogle Scholar
  117. VanWyk JJ, Hoffmann CR (1948) Periarteritis nodosa. A case of fatal exfoliative dermatitis resulting from “dilantin sodium” sensitization. Arch Intern Med 81:605Google Scholar
  118. Vining EPG, Botsford E, Freeman JM (1979) Valproate sodium in refractory seizures. Am J Dis Child 133:274PubMedGoogle Scholar
  119. Weedon AP (1975) Diphenylhydantoin sensitivity: a syndrome resembling infectious mononucleosis with a morbilliform rash and cholestatic hepatitis. Aust NJ Med 5:561Google Scholar
  120. Williams SJ, Ruppin DC, Grierson JM, Farrell GC (1986) Carbamazepine hepatitis: the clinicopathological spectrum. J Gastroenterol Hepatol 1:159Google Scholar
  121. Williams LHP, Reynolds RP, Emery JL (1983) Pancreatitis during sodium valproate treatment. Arch Dis Child 58:543PubMedGoogle Scholar
  122. Willmore LJ, Wilder BJ, Bruni J et al. (1978) Effect of valproic acid on hepatic function. Neurology 28:961PubMedGoogle Scholar
  123. Wolf R, Kahane E, Sandbank M (1985) Mycosis fungoides-like lesions associated with phenytoin therapy. Arch Dermatol 121:1181PubMedGoogle Scholar
  124. Zafrani ES, Berthelot P (1982) Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 2:648PubMedGoogle Scholar
  125. Zimmerman HJ (1991) Lesions of drug-induced liver disease and valproate toxicity. In: Levy RH, Penry JH (eds) Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. Raven, New York, pp 31–45Google Scholar
  126. Zimmerman HJ, Ishak KG (1982) Valproate induced hepatic injury: analysis of 23 fatal cases. Hepatology 2:591–598PubMedGoogle Scholar
  127. Zimmerman HJ, Maddrey WC (1993) Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER (eds) Diseases of the liver. Lippincott, Philadelphia, pp 707–769Google Scholar
  128. Zucker P, Daum F, Cohen MI (1977) Fatal carbamazepine hepatitis. J Pediatr 91:667PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • H. J. Zimmerman
  • K. G. Ishak

There are no affiliations available

Personalised recommendations